FDA panel endorses booster shot for J&J COVID-19 vaccine
Published: October 15, 2021
A panel of U.S. health advisers endorsed booster doses of Johnson & Johnson’s single-shot COVID-19 vaccine Friday, saying they should be offered at least two months after immunization.
Source: kxxv.com
Related Topics:
United StatesArnold MontoPeter MarksDrug AdministrationUniversity Of MichiganA Panel Of Us Health Advisers Endorsed Booster Doses Johnson Amp Johnsons Single Shot Covid 19 Vaccine FridayAying They Should Be Offered At Least Two Months After Immunizationj Ampj Has Asked The Food And Drug Administration For Flexibility With Its BoosterRguing The Extra Dose Adds Important Protection As Early Two Months After Initial Vaccination But That It Might Work Better If People Wait Until Six Later Fdas Advisory Panel Voted Unanimously Thata Booster Should Be Offered Without Settinga Firm Time Advisers Cited Growing Worry Recipients Ofj Ampjs Seem To Less Protected Than Who Got Pfizer Or Moderna Options And Most Single Many Ago Fda Isnt Bound By Vote Its Ultimate Decision Could Help Expand Nations Campaign Government Says All Three Us Vaccines Continue Offer Strong Against Hospitalization Death From Covid 19Nd That The Priority Is Getting First Shots To Unvaccinated But There Sa Growing Push Shore Up Protection Against Breakthrough Infections And Extra Contagious Delta Variant Of Coronavirus Booster Doses Pfizers Vaccine Began Last Month For People At High Risk Covid 19Nd The Fda Advisory Panel Has Recommended Same Approach For Moderna Recipients This Isa Breaking News Update Aps Earlier Story Follows Below Washington Ap Us Health Advisers On Friday Tackled Who Should Get Boosters Of Johnson Amp Johnsons Single Shot Covid 19 Vaccine And When Whether Usinga Competing Brand Second Dose Might Provide Better Protection Push Kicked Off Last Month After Food Drug Administration Authorized Third Doses Pfizer Seniors Younger Adults With ProblemsObs Or Living Conditions That Place Them At Higher Risk From The Coronavirus On ThursdayN Fda Advisory Panel Unanimously Recommendeda Half Dose Booster Of The Similar Moderna Vaccine For Same Groups FridayHe Same Panel Discusseda Booster Ofj Ampjs Vaccine But The Decision Is More Complex Moderna And Pfizer Asked Fda To Ok Boosters At Least Six Months After ImmunizationUtj Ampj Proposeda Sliding Schedule With An Extra Dose As Early Two Months Later Adding Another TwistHe Experts Also Will Discuss Preliminary Data Froma Government Mix And Match Study That Suggestedj Ampj Recipients May Havea Far Stronger Immune Response If They Get Eithera Moderna Or Pfizer Booster Rather Thana Secondj Dosej Ampjs Single Shot Vaccine Is Made Witha Different Technology Than The Two Vaccines It Has Consistently Shown Lower Effectiveness Levels On FridayJ Ampj Executives Pitcheda Booster Asa Way To Strengthena Robust Vaccine That They Said Has Retained Its Protective Power Over Eight Months But Fda Scientists Pointedly Challenged Assertion There Are Data Suggest The Effectiveness Of This Is Actually Less Than Companys Presentation HereAid Dr Peter MarksDas Top Vaccines Official And That Isa Finding Of Concern Particularly Because Thats Been Seen In Minority Communities Potentially Others The Panels Chair Said Regulators Havea Responsibility To Shore Up Protection Forj Ampj Recipients There Is Some Urgency Here Do SomethingAid Dr Arnold Monto Of The University Michigan Fda Will Use Its Advisers Recommendations To Decide Whether Authorize Boosters For Bothj Ampj And ModernaFter Which Another Government Agency Will Rule On Who Should Roll Up Their Sleeves All Three Vaccines In The Us Still Offer Strong Protection Against Severe Illness And Death From Covid 19 Nations Priority Remains Getting First Doses To 66 Million Eligible But Unvaccinated Americans Are Most At Risk As Extra Contagious Delta Variant Continues Circulatej Ampj Presented Results Froma Large Study That Found Givinga Second Dose Just Two Months After Bumped Symptomatic 94 70 Recipients Giving Booster Six Later Instead Prompted An Even Bigger Jump Virus Fighting Antibodies Own ReviewDa Scientists Flaggeda Number Of Shortcomings Withj Ampjs Booster StudiesNcluding Onlya Tiny Portion Of Cases Involving The Delta VariantY Far The Dominant Strain In Us Reviewers Also Warned Thatj Ampj Had Only Followed Booster Recipients Fora Little More Thana Month Aftera Second DoseAking It Hard To Draw Conclusions About The Durability Of Protection FinallyDa Staff Emphasized That They Had Not Time To Independently Confirmj Ampjs Findings